The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function.
Saved in:
| Title: | The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function. |
|---|---|
| Authors: | Manzo A; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy., Grassi ES; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy., Borghi MO; Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy., Colombo C; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy., Persani L; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy., Cirello V; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. |
| Source: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2026 May 08; Vol. 17, pp. 1743111. Date of Electronic Publication: 2026 May 08 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42181208 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Manzo+A%22">Manzo A</searchLink>; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Grassi+ES%22">Grassi ES</searchLink>; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Borghi+MO%22">Borghi MO</searchLink>; Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Colombo+C%22">Colombo C</searchLink>; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Persani+L%22">Persani L</searchLink>; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Cirello+V%22">Cirello V</searchLink>; Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101555782%22">Frontiers in endocrinology</searchLink> [Front Endocrinol (Lausanne)] 2026 May 08; Vol. 17, pp. 1743111. <i>Date of Electronic Publication: </i>2026 May 08 (<i>Print Publication: </i>2026). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101555782 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2392 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642392%22">16642392 </searchLink><i>NLM ISO Abbreviation: </i>Front Endocrinol (Lausanne) <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42181208 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fendo.2026.1743111 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1743111 Titles: – TitleFull: The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Manzo A – PersonEntity: Name: NameFull: Grassi ES – PersonEntity: Name: NameFull: Borghi MO – PersonEntity: Name: NameFull: Colombo C – PersonEntity: Name: NameFull: Persani L – PersonEntity: Name: NameFull: Cirello V IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 05 Text: 2026 May 08 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 1664-2392 Numbering: – Type: volume Value: 17 Titles: – TitleFull: Frontiers in endocrinology Type: main |
| ResultId | 1 |
